Q3 Earnings Forecast for Immunovant Issued By Zacks Research

by · The Markets Daily

Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Equities researchers at Zacks Research boosted their Q3 2026 EPS estimates for shares of Immunovant in a research report issued on Thursday, December 18th. Zacks Research analyst Team now anticipates that the company will earn ($0.76) per share for the quarter, up from their prior forecast of ($0.77). The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. Zacks Research also issued estimates for Immunovant’s Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.91) EPS, Q3 2027 earnings at ($0.89) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($3.05) EPS, Q1 2028 earnings at ($0.73) EPS, Q2 2028 earnings at ($0.70) EPS and FY2028 earnings at ($2.68) EPS.

Immunovant (NASDAQ:IMVT – Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.01). During the same period in the prior year, the company earned ($0.74) EPS.

Other research analysts have also recently issued research reports about the company. Truist Financial began coverage on Immunovant in a research report on Tuesday, October 14th. They set a “hold” rating and a $16.00 price target on the stock. The Goldman Sachs Group boosted their price objective on Immunovant from $18.00 to $28.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. JPMorgan Chase & Co. cut their target price on shares of Immunovant from $37.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunovant in a research note on Tuesday, October 14th. Finally, Guggenheim reissued a “buy” rating and issued a $41.00 price target on shares of Immunovant in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.63.

Get Our Latest Stock Analysis on Immunovant

Immunovant Trading Down 2.8%

Shares of NASDAQ IMVT opened at $26.76 on Monday. The stock has a fifty day simple moving average of $23.07 and a two-hundred day simple moving average of $18.62. Immunovant has a 1-year low of $12.72 and a 1-year high of $27.69. The firm has a market cap of $4.69 billion, a price-to-earnings ratio of -9.42 and a beta of 0.56.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IMVT. Strs Ohio bought a new position in Immunovant during the 1st quarter valued at about $27,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Immunovant in the third quarter worth approximately $33,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Immunovant during the first quarter valued at approximately $37,000. Farther Finance Advisors LLC lifted its position in Immunovant by 142,750.0% during the second quarter. Farther Finance Advisors LLC now owns 2,857 shares of the company’s stock valued at $46,000 after purchasing an additional 2,855 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in Immunovant by 138.9% in the third quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock worth $46,000 after purchasing an additional 1,646 shares during the last quarter. 47.08% of the stock is owned by institutional investors.

Insider Activity

In related news, COO Melanie Gloria sold 12,626 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $23.62, for a total transaction of $298,226.12. Following the completion of the transaction, the chief operating officer owned 173,511 shares of the company’s stock, valued at approximately $4,098,329.82. The trade was a 6.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Jay S. Stout sold 2,520 shares of the company’s stock in a transaction that occurred on Wednesday, October 22nd. The stock was sold at an average price of $19.03, for a total transaction of $47,955.60. Following the sale, the chief technology officer directly owned 200,814 shares in the company, valued at $3,821,490.42. This trade represents a 1.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 68,660 shares of company stock valued at $1,599,001. 1.80% of the stock is currently owned by insiders.

About Immunovant

(Get Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.

See Also